Loading
companiesCompany
AstraZeneca
AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.
Also called: Acerta PharmaAlexion PharmaceuticalsMedImmune LLCMedImmune
Overview
AstraZeneca's oncology revenue exceeds $20B. ADCs (T-DXd, Dato-DXd with Daiichi Sankyo; AZD0901 CLDN18.2; puxitatug samrotecan B7-H4; tilatamig samrotecan EGFR×MET bsADC), osimertinib, olaparib, capivasertib, durvalumab, camizestrant, saruparib, and radioconjugates via Fusion Pharma (225Ac-PSMA). Also cell therapy (Neogene, GPC3 CAR-T).
Headquarters
Cambridge, GB
Scorecard
All companies#5of 1244 companies, score 257
- approved products +96
- phase 3 +30
- phase 1/2 +20
- targets +40
- modalities +20
- regions +7
- 24-month regulatory events +20
- registry trials +30
- failures -6
16 approved, 10 in phase 3, 20 earlier, 32 targets, 4,043 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-03-19 | Fusion Pharmaceuticals (AstraZeneca) to AstraZeneca FPI-2265 (actinium-225 PSMA) and the Fusion targeted alpha therapy platform | Acquisition | $2.0bn | up to $2.4bn including a contingent value right | source |
| 2023-12-26 | Gracell Biotechnologies to AstraZeneca GC012F (AZD0120), BCMA x CD19 CAR-T, and the FasTCAR platform | Acquisition | $1.0bn | up to $1.2bn including a contingent value right | source |
| 2023-02 | Keymed Biosciences (KYM Biosciences) to AstraZeneca CMG901 (sonesitatug vedotin, AZD0901), Claudin 18.2 ADC | Licence | $63m | up to $1.19bn | source |
| 2020-07-27 | Daiichi Sankyo to AstraZeneca Datopotamab deruxtecan (DS-1062, Datroway) | Co-development | $1.0bn | up to $6.0bn | source |
| 2019-03-28 | Daiichi Sankyo to AstraZeneca Trastuzumab deruxtecan (DS-8201, Enhertu) | Co-development | $1.35bn | up to $6.9bn | source |
Catalysts
What is due next- 2027expectedTROPION-Lung14: datopotamab deruxtecan plus osimertinib, first-line EGFR-mutant NSCLC
Would move the TROP2 ADC into the first-line EGFR-mutant setting on top of the standard TKI. Timing is a registry-based estimate. Source
Type
Large pharma · AZN
Stage
Public
Website
ApprovedADC
Trastuzumab deruxtecan · Enhertu
Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.
ApprovedADC
Datopotamab deruxtecan · Datroway
Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy.
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza
Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.
ApprovedSmall-molecule AKT inhibitor
Capivasertib · Truqap
Capivasertib (Truqap) is the first AKT inhibitor, for breast cancer with PI3K-pathway mutations and, since 2026, for prostate cancer with PTEN loss.
ApprovedMonoclonal antibody (anti-PD-L1)
Durvalumab · Imfinzi
A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.
Phase 2Bispecific ADC
AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.
Phase 3ADC
Sonesitatug vedotin is a Claudin 18.2 ADC in phase 3 for gastric cancer, licensed by AstraZeneca from KYM Biosciences.
Phase 2ADC
Puxitatug samrotecan is a B7-H4 ADC targeting a checkpoint-like protein enriched in breast, ovarian, and endometrial cancers.
Phase 3Targeted alpha therapy
Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.
Phase 3monoclonal antibody
Domvanalimab is an experimental monoclonal antibody from Gilead Sciences in phase 3 trials for non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
Phase 3antibody (INN stem -mab; form not stated in the registry record)
Oleclumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer, with its target not yet stated publicly.
Phase 3small molecule
Ceralasertib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for non-small-cell lung cancer, melanoma and triple-negative breast cancer, aimed at ATR.
Phase 3small molecule
Saruparib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for prostate cancer, ovarian cancer and non-small-cell lung cancer, aimed at PARP.
Phase 3antibody (INN stem -mab; form not stated in the registry record)
Monalizumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
Phase 3ADC
AZD5335 is an experimental antibody-drug conjugate from AstraZeneca in phase 3 trials for ovarian cancer, with its target not yet stated publicly.
Phase 3bispecific antibody
AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.
Phase 2radioligand
FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA.
Phase 2small molecule
AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).
Phase 2T-cell engager
AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.
Phase 2ADC
AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.
Phase 2bispecific antibody
Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.
Phase 2T-cell engager
AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.
Phase 2small molecule
Palacaparib is an experimental small-molecule drug from AstraZeneca in phase 2 trials for ovarian cancer, non-small-cell lung cancer and endometrial cancer, aimed at PARP.
Phase 2protein degrader
AZD9750 is an experimental protein degrader from AstraZeneca in phase 2 trials for prostate cancer, aimed at Androgen receptor.
Phase 2ADC
AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.
Phase 2T-cell engager
AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.
Phase 2CAR-T cell therapy
AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.
Phase 2bispecific antibody
AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.
Phase 2bispecific antibody
AZD5863 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer, aimed at Claudin 18.2 and CD3.
Phase 2Small-molecule inhibitor
AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.
Phase 2CAR-T cell therapy
GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.
ApprovedInjectable SERD
Fulvestrant · Faslodex
Fulvestrant is a monthly intramuscular injection that degrades the oestrogen receptor rather than blocking it, the endocrine backbone paired with CDK4/6, PI3K and AKT inhibitors once aromatase inhibitors fail. Slow uptake and incomplete receptor degradation drove the search for oral degraders.
EstablishedAntifolate thymidylate synthase inhibitor, intravenous every three weeks
Raltitrexed · Tomudex
Raltitrexed is a three-weekly intravenous antifolate used in Europe, Canada and Australia for advanced bowel cancer, and with cisplatin for mesothelioma, in patients who cannot take fluorouracil.
ApprovedSmall-molecule SERM
Tamoxifen · Nolvadex
The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.
EstablishedLong-acting anti-complement C5 monoclonal antibody
Ravulizumab · Ultomiris
Ravulizumab is an eight-weekly infusion that blocks the complement system; it treats paroxysmal nocturnal haemoglobinuria, a clonal bone marrow disorder managed by haematologists alongside aplastic anaemia and myelodysplasia.
ApprovedSmall-molecule covalent BTK inhibitor (second generation)
Acalabrutinib · Calquence
Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen.
Phase 2Oral serine/threonine kinase inhibitor
Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.
ApprovedOral non-steroidal aromatase inhibitor
Anastrozole · Arimidex
Anastrozole is a daily tablet that stops the body making oestrogen after the menopause. It treats and prevents hormone-receptor-positive breast cancer and is an alternative to tamoxifen after surgery for ductal carcinoma in situ.
Phase 3CAR-T cell therapy
AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.
ApprovedOral first-generation non-steroidal antiandrogen
Bicalutamide · Casodex
The old antiandrogen pill used to block the testosterone flare from GnRH agonists and in combined androgen blockade; superseded by enzalutamide-class drugs.
ApprovedOral SERD
Camizestrant · Etcamah
Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.
Phase 2Oral VEGFR 1-3 tyrosine kinase inhibitor
Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.
ApprovedSmall-molecule EGFR TKI (first generation, reversible)
Gefitinib · Iressa
The lung-cancer pill whose dramatic responses in a few patients led to the discovery of EGFR mutations in 2004.
WithdrawnAnti-CD22 immunotoxin (Pseudomonas exotoxin A fragment)
Moxetumomab pasudotox · Lumoxiti
An immunotoxin for hairy cell leukaemia that produced lasting remissions in relapsed patients but was withdrawn from sale in 2023 for commercial reasons.
ApprovedSmall-molecule selective MET TKI
Savolitinib · Orpathys
Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.
ApprovedSmall-molecule allosteric MEK1/2 inhibitor
Selumetinib · Koselugo
Selumetinib (Koselugo) is the first medicine for children and adults with neurofibromatosis type 1 whose plexiform neurofibromas, benign but disfiguring and painful nerve tumours, cannot be removed by surgery.
ApprovedMonoclonal antibody (anti-CTLA-4)
Tremelimumab · Imjudo
Tremelimumab is AstraZeneca's CTLA-4 antibody, given as a single priming dose with durvalumab and chemotherapy in lung and liver cancer.
Phase 2Oral serine/threonine kinase inhibitor
Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
Withdrawnsmall molecule
A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped.
rctJournal of Thoracic Oncology 20260 citations
ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer
The survival benefit first reported in 2023 has held five years after the last dose of adjuvant osimertinib, which answers the worry that a three-year course only delays relapse. Patients with an exon 19 deletion gained most; the L858R estimate crosses one and is less certain. Nothing here changes the recommendation, which already rests on the 2023 analysis, but it tightens the case for testing every resected non-squamous tumour for EGFR mutations.
rctAnnals of Oncology 20269 citations
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
The latest in a line of negative targeted-therapy trials in triple-negative disease (EGFR, VEGF, iniparib, now AKT): a modest delay in progression that did not translate into survival, in the same year that an antibody-drug conjugate did. It is why the roadmap treats pathway-targeted small molecules as the road not taken.
rctAnnals of Oncology 2026changed practice14 citations
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
The first-line overall survival result that made an antibody-drug conjugate the standard for PD-L1-negative or immunotherapy-ineligible metastatic triple-negative disease, and the reason the sequencing question (which TROP2 drug first, what after it) is now urgent.
observationalESMO Open 20260 citations
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02
The IHC 3+ subgroup result is why the tumour-agnostic label is written at 3+ and not 2+, and why a gallbladder cancer with a strong HER2 stain now has two on-label choices (zanidatamab, trastuzumab deruxtecan) after chemotherapy. Lung toxicity again ran higher than in breast cancer.
rctLung Cancer 20260 citations
FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer
For a patient weighing the FLAURA2 regimen against osimertinib alone, the extra toxicity is front-loaded: the hardest months are the four induction cycles, and once pemetrexed stops the profile returns to that of osimertinib by itself. Kidney function deserves watching during pemetrexed maintenance.
rctAnnals of Oncology 2026changed practice0 citations
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.
rctESMO Open 20260 citations
TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer
Chinese patients in the trial saw the same pattern as the global population: a clear progression-free survival gain, no proven survival gain, and a different rather than heavier side-effect burden, with mouth and eye toxicity in nearly half. It supports use of datopotamab deruxtecan in this setting in China but does not resolve the global trial's missing survival benefit.
rctJournal of Clinical Oncology 2025changed practice
Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
23 more, oldest last
AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patientsDurvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 studyADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancerDESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancerNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancerOsimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLCTrastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trialTROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survivalOsimertinib with or without chemotherapy in EGFR-mutated advanced NSCLCPerioperative durvalumab for resectable non-small-cell lung cancerDESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancerDESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable groupFive-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancerOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerOlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancerADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancerCapivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trialELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLLDurvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumoursFLAURA: osimertinib as first treatment for EGFR-mutated lung cancerSOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancerPACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer
Similar pages
- CompanyDaiichi Sankyo
Shares A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer, A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02), A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors, A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer.
- TechnologyTopoisomerase-I inhibitors (and ADC payloads)
Shares A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations, A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC, A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02), A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors.
- TechnologyAntibody-drug conjugate (ADC)
Shares A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations, A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer, Moxetumomab pasudotox, Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01).
- TechnologyPARP inhibitors
Shares Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib, D9319C00001- 1L OC Mono Global RCT, Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002), FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- TechnologySmall-molecule kinase inhibitors
Shares An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma, An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia, Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study, Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign.
- TreatmentCarboplatin
Shares To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations, Volrustomig Priming Regimens Exploratory Phase II Platform Study, A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s, A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung.
- TreatmentCisplatin
Shares CALLA, Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC, Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer, To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations.
- TechnologyImmune checkpoint inhibitors
Shares A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment, A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy, Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer., Durvalumab and Tremelimumab for Pediatric Malignancies.
cancers
Biliary tract cancer (cholangiocarcinoma)Bladder & urothelial cancerBRCA or PALB2-mutant pancreatic ductal adenocarcinomaChronic lymphocytic leukaemiaEGFR-mutated non-small-cell lung cancerEndometrial cancerExtensive-stage small-cell lung cancerGallbladder cancerGastric & gastro-oesophageal junction cancerHairy cell leukaemiaHepatocellular carcinomaHER2-mutant non-small-cell lung cancerHER2-positive breast cancerHR-positive / HER2-negative breast cancerLimited-stage small-cell lung cancerMantle cell lymphomaMET exon 14 and MET-amplified non-small-cell lung cancerMetastatic pancreatic ductal adenocarcinomaNon-small-cell lung cancerOesophageal cancerOvarian cancerPancreatic ductal adenocarcinomaProstate cancerResectable stage I to III non-small-cell lung cancerSmall-cell lung cancerThyroid cancerTriple-negative breast cancer (TNBC)Unresectable stage III non-small-cell lung cancerWaldenström macroglobulinaemia
fronts
technologies
targets
drugs
ApprovedSmall-molecule covalent BTK inhibitor (second generation)
Acalabrutinib · Calquence
Phase 3Targeted alpha therapy
Phase 2Oral serine/threonine kinase inhibitor
ApprovedOral non-steroidal aromatase inhibitor
Anastrozole · Arimidex
Phase 3CAR-T cell therapy
Phase 3bispecific antibody
Phase 2small molecule
Phase 2CAR-T cell therapy
Phase 2ADC
Phase 2ADC
Phase 3ADC
Phase 2T-cell engager
Phase 2bispecific antibody
Phase 2T-cell engager
Phase 2bispecific antibody
Phase 2Small-molecule inhibitor
Phase 2protein degrader
Phase 2T-cell engager
ApprovedOral first-generation non-steroidal antiandrogen
Bicalutamide · Casodex
ApprovedOral SERD
Camizestrant · Etcamah
ApprovedSmall-molecule AKT inhibitor
Capivasertib · Truqap
Phase 2Oral VEGFR 1-3 tyrosine kinase inhibitor
Phase 3small molecule
ApprovedADC
Datopotamab deruxtecan · Datroway
Phase 3monoclonal antibody
ApprovedMonoclonal antibody (anti-PD-L1)
Durvalumab · Imfinzi
Phase 2radioligand
ApprovedInjectable SERD
Fulvestrant · Faslodex
Phase 2CAR-T cell therapy
ApprovedSmall-molecule EGFR TKI (first generation, reversible)
Gefitinib · Iressa
Phase 3antibody (INN stem -mab; form not stated in the registry record)
WithdrawnAnti-CD22 immunotoxin (Pseudomonas exotoxin A fragment)
Moxetumomab pasudotox · Lumoxiti
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza
Phase 3antibody (INN stem -mab; form not stated in the registry record)
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
Phase 2small molecule
Phase 2ADC
EstablishedAntifolate thymidylate synthase inhibitor, intravenous every three weeks
Raltitrexed · Tomudex
EstablishedLong-acting anti-complement C5 monoclonal antibody
Ravulizumab · Ultomiris
Phase 2bispecific antibody
Phase 3small molecule
ApprovedSmall-molecule selective MET TKI
Savolitinib · Orpathys
ApprovedSmall-molecule allosteric MEK1/2 inhibitor
Selumetinib · Koselugo
Phase 3ADC
ApprovedSmall-molecule SERM
Tamoxifen · Nolvadex
Phase 2Bispecific ADC
ApprovedADC
Trastuzumab deruxtecan · Enhertu
ApprovedMonoclonal antibody (anti-CTLA-4)
Tremelimumab · Imjudo
companies
institutions
trials
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-sA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell LungA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionA Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerA Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)A Phase 2 Study of ABSK043 Combined With OsimertinibA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomA Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following CA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainA Platform Study in Non-Small Cell Lung Cancer (NSCLC)A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCA Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung CanceA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With RelaA Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCA Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyA Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerA Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancerand 225 more →
roadmaps
Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trialsLymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruitingPancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance questionTriple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem
ideas
A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancerReflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecanTest every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later
people
bottlenecks
key papers
Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphomaADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancerADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancerADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancerAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patientsCapivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trialCapivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trialDatopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trialDESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancerDESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable groupDESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancerDurvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 studyDurvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLLFive-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancerFLAURA: osimertinib as first treatment for EGFR-mutated lung cancerFLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancerNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancerOlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancerOsimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLCOsimertinib with or without chemotherapy in EGFR-mutated advanced NSCLCOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerPACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancerPAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumoursPerioperative durvalumab for resectable non-small-cell lung cancerSOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancerSustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trialTrastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trialTROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancerTROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
AstraZeneca's open generative molecular design framework.
AstraZeneca's sensitive variant caller for targeted sequencing, including low-frequency somatic variants and tumour-normal pairs.